1
|
Salvador C, Andreozzi P, Romero G, Loinaz I, Dupin D, Moya SE. Self-Assembled Oleic Acid-Modified Polyallylamines for Improved siRNA Transfection Efficiency and Lower Cytotoxicity. ACS APPLIED BIO MATERIALS 2023; 6:529-542. [PMID: 36647574 PMCID: PMC9945087 DOI: 10.1021/acsabm.2c00845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Small interference RNA (siRNA) is a tool for gene modulation, which can silence any gene involved in genetic disorders. The potential of this therapeutic tool is hampered by RNA instability in the blood stream and difficulties to reach the cytosol. Polyamine-based nanoparticles play an important role in gene delivery. Polyallylamine hydrochloride (PAH) is a polycation displaying primary amines that can be easily chemically modified to match the balance between cell viability and siRNA transfection. In this work, PAH has been covalently functionalized with oleic acid at different molar ratios by carbodiimide chemistry. The substituted polymers form polyplexes that keep positive surface charge and fully encapsulate siRNA. Oleic acid substitution improves cell viability in the pulmonary cell line A549. Moreover, 6 and 14% of oleic acid substitution show an improvement in siRNA transfection efficiency. CD47 is a ubiquitous protein which acts as "don't eat me signal." SIRPα protein of macrophages recognizes CD47, leading to tumor cell phagocytosis by macrophages. By knocking down CD47 with siRNA, cancer cells become vulnerable to be eliminated by the immune system. PAH-oleic acid substitutes show high efficacy in silencing the CD47 protein, making them a potential candidate for immunotherapy.
Collapse
Affiliation(s)
- Cristian Salvador
- CIC
biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián20014, Spain,CIDETEC,
Basque Research and Technology Alliance (BRTA), Parque Científico
y Tecnológico de Gipuzkoa, Miramon Pasealekua, 196, Donostia-San Sebastián20014, Spain
| | - Patrizia Andreozzi
- Consorzio
Sistemi a Grande Interfase, Department of Chemistry ‘Ugo Schiff’, University of Florence, Via della Lastruccia 3, Sesto Fiorentino50019, Florence, Italy
| | - Gabriela Romero
- Department
of Biomedical Engineering and Chemical Engineering, The University of Texas at San Antonio, San Antonio78249, Texas, United States
| | - Iraida Loinaz
- CIDETEC,
Basque Research and Technology Alliance (BRTA), Parque Científico
y Tecnológico de Gipuzkoa, Miramon Pasealekua, 196, Donostia-San Sebastián20014, Spain
| | - Damien Dupin
- CIDETEC,
Basque Research and Technology Alliance (BRTA), Parque Científico
y Tecnológico de Gipuzkoa, Miramon Pasealekua, 196, Donostia-San Sebastián20014, Spain,. Phone: +34 943 30 90 22
| | - Sergio E. Moya
- CIC
biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián20014, Spain,. Phone: +34 943 00 53 11
| |
Collapse
|
2
|
Rezaee M, Oskuee RK, Nassirli H, Malaekeh-Nikouei B. Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems. J Control Release 2016; 236:1-14. [DOI: 10.1016/j.jconrel.2016.06.023] [Citation(s) in RCA: 114] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 06/12/2016] [Accepted: 06/13/2016] [Indexed: 01/05/2023]
|
3
|
A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML. BIOMED RESEARCH INTERNATIONAL 2016; 2016:1287128. [PMID: 27034925 PMCID: PMC4807046 DOI: 10.1155/2016/1287128] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 12/27/2015] [Indexed: 02/05/2023]
Abstract
Limited success of antisense oligonucleotides (ASO) in clinical anticancer therapy calls for more effective delivery carriers. The goal of this study was to develop a nanoparticle system for delivery of ASO G3139, which targets mRNA of antiapoptotic protein Bcl-2, to acute myeloid leukemia (AML) cells. The synthesized nanoparticle Tf-LPN-G3139 contained a small molecular weight polyethylenimine and two cationic lipids as condensing agents, with transferrin on its surface for selective binding and enhanced cellular uptake. The optimized nitrogen to phosphate (N/P) ratio was 4 to achieve small particle size and high G3139 entrapment efficiency. The Tf-LPN-G3139 exhibited excellent colloidal stability during storage for at least 12 weeks and remained intact for 4 hours in nuclease-containing serum. The cellular uptake results showed extensive internalization of fluorescence-labelled G3139 in MV4-11 cells through Tf-LPN. Following transfection, Tf-LPN-G3139 at 1 µM ASO level induced 54% Bcl-2 downregulation and >20-fold apoptosis compared to no treatment. When evaluated in mice bearing human xenograft AML tumors, Tf-LPN-G3139 suppressed tumor growth by ~60% at the end of treatment period, accompanied by remarkable pharmacological effect of Bcl-2 inhibition in tumor. In conclusion, Tf-LPN-G3139 is a promising nanoparticle system for ASO G3139 delivery to AML and warrants further investigations.
Collapse
|
4
|
Wang Y, Miao L, Satterlee A, Huang L. Delivery of oligonucleotides with lipid nanoparticles. Adv Drug Deliv Rev 2015; 87:68-80. [PMID: 25733311 DOI: 10.1016/j.addr.2015.02.007] [Citation(s) in RCA: 130] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Revised: 02/13/2015] [Accepted: 02/18/2015] [Indexed: 01/16/2023]
Abstract
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recognized as powerful tools that can treat a broad spectrum of diseases. The discoveries of novel regulatory methods of gene expression with diverse mechanisms of action are still driving the development of novel ON-based therapeutics. Difficulties in the delivery of this class of therapeutics hinder their in vivo applications, which forces drug delivery systems to be a prerequisite for clinical translation. This review discusses the strategy of using lipid nanoparticles as carriers to deliver therapeutic ONs to target cells in vitro and in vivo. A discourse on how chemical and physical properties of the lipid materials could be utilized during formulation and the resulting effects on delivery efficiency constitutes the major part of this review.
Collapse
|
5
|
Li H, Xu S, Quan J, Yung BC, Pang J, Zhou C, Cho YA, Zhang M, Liu S, Muthusamy N, Chan KK, Byrd JC, Lee LJ, Marcucci G, Lee RJ. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia. Mol Pharm 2015; 12:2010-8. [PMID: 25871632 DOI: 10.1021/mp5008212] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
CD33-targeted lipid nanoparticles (aCD33LNs) were synthesized for delivery of GTI-2040, an antisense oligonucleotide (ASO) against the R2 subunit of ribonucleotide reductase, to acute myelogenous leukemia (AML). These LNs incorporated a deoxycholate-polyethylenimine (DOC-PEI) conjugate, which has shown significant activity to facilitate oligonucleotide delivery. Anti-CD33 scFv (aCD33) was added as a targeting ligand. The delivery efficiency of this system was investigated both in vitro and in vivo. When cells were treated with aCD33LN/GTI-2040, significant uptake was observed in CD33 positive Kasumi-1 cells. aCD33LNs loaded with GTI-2040 induced significant down-regulation of R2 mRNA and protein levels in AML cells. Moreover, aCD33LN/GTI-2040 showed a 15-fold reduction in the IC50 of antileukemic drug Ara-C in Kasumi-1 cells. In Kasumi-1 xenograft model, aCD33LN/GTI-2040 showed significant R2 downregulation compared to LN/GTI-2040. Furthermore, aCD33LN/GTI-2040 coadministered with Ara-C was shown to be highly effective in tumor growth inhibition and to greatly increase survival time of mice bearing Kasumi-1 xenograft tumors. The conjugate DOC-PEI has shown an ability to include calcein release from lipid nanoparticles, suggesting a potential mechanism contributing to efficient endosome release by DOC-PEI2K. These results indicate that aCD33LNs are a highly effective vehicle for the therapeutic delivery of antisense agents to AML.
Collapse
Affiliation(s)
- Hong Li
- †Division of Pharmaceutics, College of Pharmacy, ‡Division of Hematology-Oncology, §Molecular, Cellular and Developmental Biology Program, and ∥Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States
| | - Songlin Xu
- †Division of Pharmaceutics, College of Pharmacy, ‡Division of Hematology-Oncology, §Molecular, Cellular and Developmental Biology Program, and ∥Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States
| | - Jishan Quan
- †Division of Pharmaceutics, College of Pharmacy, ‡Division of Hematology-Oncology, §Molecular, Cellular and Developmental Biology Program, and ∥Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States.,⊥Pharmacy College, Yanbian University, Yanji, Jilin 133002, China
| | - Bryant C Yung
- †Division of Pharmaceutics, College of Pharmacy, ‡Division of Hematology-Oncology, §Molecular, Cellular and Developmental Biology Program, and ∥Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States
| | | | - Chenguang Zhou
- †Division of Pharmaceutics, College of Pharmacy, ‡Division of Hematology-Oncology, §Molecular, Cellular and Developmental Biology Program, and ∥Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States
| | - Young-Ah Cho
- †Division of Pharmaceutics, College of Pharmacy, ‡Division of Hematology-Oncology, §Molecular, Cellular and Developmental Biology Program, and ∥Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States
| | | | | | | | - Kenneth K Chan
- †Division of Pharmaceutics, College of Pharmacy, ‡Division of Hematology-Oncology, §Molecular, Cellular and Developmental Biology Program, and ∥Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States
| | | | | | | | - Robert J Lee
- †Division of Pharmaceutics, College of Pharmacy, ‡Division of Hematology-Oncology, §Molecular, Cellular and Developmental Biology Program, and ∥Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States
| |
Collapse
|
6
|
Pinel S, Aman E, Erblang F, Dietrich J, Frisch B, Sirman J, Kichler A, Sibler AP, Dontenwill M, Schaffner F, Zuber G. Quantitative measurement of delivery and gene silencing activities of siRNA polyplexes containing pyridylthiourea-grafted polyethylenimines. J Control Release 2014; 182:1-12. [DOI: 10.1016/j.jconrel.2014.03.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 02/24/2014] [Accepted: 03/01/2014] [Indexed: 01/11/2023]
|
7
|
Introduction of pH-sensitive upper critical solution temperature (UCST) properties into branched polyethylenimine. POLYMER 2013. [DOI: 10.1016/j.polymer.2013.07.061] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
8
|
Uddin MN, Patel NJ, Bhowmik T, D'Souza B, Akalkotkar A, Etzlar F, Oettinger CW, D'Souza M. Enhanced bioavailability of orally administered antisense oligonucleotide to nuclear factor kappa B mRNA after microencapsulation with albumin. J Drug Target 2013; 21:450-7. [PMID: 23480723 DOI: 10.3109/1061186x.2013.765440] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Antisense molecules that pertain to ribonucleic acid (RNA) and complementary to the messenger RNA (mRNA) are produced by transcription of a given gene. Antisense oligonucleotides have emerged as potential gene-specific therapeutic agents that are currently undergoing evaluation in clinical trials for a variety of diseases. When administered orally, antisense oligionucleotides have poor bioavailability as they are rapidly degraded by the acid in the stomach and by the enzymes in the intestine. Therefore, the enhancement of bioavailability after oral administration is highly desirable. This article shows the enhanced bioavailability of antisense oligonucleotides that targets nuclear factor kappa B (NF-κB) mRNA after encapsulating in an inert, biodegradable albumin polymer matrix that was administered via the oral route into a rat model. The bioavailability of the antisense oligonucleotides to NF-κB in microencapsulated form was compared to the solution form of the drug upon oral administration. The solution form had a low bioavailability of 9%, whereas the bioavailability for the microencapsulated form of the drug increased up to 70%. Moreover, the other pharmacokinetic parameters including half-life (t1/2) and volume of distribution (Vd) increased for the microencapsulated form compared to the solution form of the drug.
Collapse
|
9
|
Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012; 33:4889-906. [DOI: 10.1016/j.biomaterials.2012.03.046] [Citation(s) in RCA: 437] [Impact Index Per Article: 36.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2012] [Accepted: 03/13/2012] [Indexed: 11/16/2022]
|
10
|
Pyridylthiourea-grafted polyethylenimine offers an effective assistance to siRNA-mediated gene silencing in vitro and in vivo. J Control Release 2012; 157:418-26. [DOI: 10.1016/j.jconrel.2011.10.007] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2011] [Revised: 10/05/2011] [Accepted: 10/06/2011] [Indexed: 12/15/2022]
|
11
|
Caracciolo G, Pozzi D, Capriotti AL, Marianecci C, Carafa M, Marchini C, Montani M, Amici A, Amenitsch H, Digman MA, Gratton E, Sanchez SS, Laganà A. Factors Determining the Superior Performance of Lipid/DNA/Protammine Nanoparticles over Lipoplexes. J Med Chem 2011; 54:4160-71. [DOI: 10.1021/jm200237p] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Giulio Caracciolo
- Department of Molecular Medicine, “Sapienza” University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy
| | - Daniela Pozzi
- Department of Molecular Medicine, “Sapienza” University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy
| | - Anna Laura Capriotti
- Department of Chemistry, “Sapienza” University of Rome, P.le A. Moro 5, 00185 Rome, Italy
| | - Carlotta Marianecci
- Department of Drug Chemistry and Technologies, Faculty of Pharmacy, “Sapienza” University of Rome, P.le A. Moro 5, 00185 Rome, Italy
| | - Maria Carafa
- Department of Drug Chemistry and Technologies, Faculty of Pharmacy, “Sapienza” University of Rome, P.le A. Moro 5, 00185 Rome, Italy
| | - Cristina Marchini
- Department of Bioscience and Biotechnology, University of Camerino, Via Gentile III da Varano, 62032 Camerino (MC), Italy
| | - Maura Montani
- Department of Bioscience and Biotechnology, University of Camerino, Via Gentile III da Varano, 62032 Camerino (MC), Italy
| | - Augusto Amici
- Department of Bioscience and Biotechnology, University of Camerino, Via Gentile III da Varano, 62032 Camerino (MC), Italy
| | - Heinz Amenitsch
- Institute of Biophysics and Nanosystems Research, Austrian Academy of Sciences, Schmiedelstrasse 6, A-8042 Graz, Austria
| | - Michelle A. Digman
- Laboratory for Fluorescence Dynamics, Department of Biomedical Engineering, University of California, Irvine, 3120 Natural Sciences 2, Irvine, California 92697-2715, United States
| | - Enrico Gratton
- Laboratory for Fluorescence Dynamics, Department of Biomedical Engineering, University of California, Irvine, 3120 Natural Sciences 2, Irvine, California 92697-2715, United States
| | - Susana S. Sanchez
- Laboratory for Fluorescence Dynamics, Department of Biomedical Engineering, University of California, Irvine, 3120 Natural Sciences 2, Irvine, California 92697-2715, United States
- Microscopy and Dynamic Imaging Unit, Centro Nacional de Investigaciones Cardiovasculares, Fundación CNIC-Carlos III, Madrid, Spain
| | - Aldo Laganà
- Department of Chemistry, “Sapienza” University of Rome, P.le A. Moro 5, 00185 Rome, Italy
| |
Collapse
|